What is Lixte Biotechnology Holdings Cash Flow from Operations?
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lixte Biotechnology Holdings Cash Flow from Operations Chart
Lixte Biotechnology Holdings Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Lixte Biotechnology Holdings's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (NAS:LIXT) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Lixte Biotechnology Holdings's net income from continuing operations for the
three
months ended in Mar. 2024 was $-0.97 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Lixte Biotechnology Holdings's depreciation, depletion and amortization for the
three
months ended in Mar. 2024 was $0.00 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Lixte Biotechnology Holdings's change in working capital for the
three
months ended in Mar. 2024 was $0.08 Mil. It means Lixte Biotechnology Holdings's working capital
increased by $0.08 Mil
from Dec. 2023 to Mar. 2024 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Lixte Biotechnology Holdings's cash flow from deferred tax for the
three
months ended in Mar. 2024 was $0.00 Mil.
Lixte Biotechnology Holdings's cash from discontinued operating Activities for the
three
months ended in Mar. 2024 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Lixte Biotechnology Holdings's asset impairment charge for the
three
months ended in Mar. 2024 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Lixte Biotechnology Holdings's stock based compensation for the
three
months ended in Mar. 2024 was $0.10 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Lixte Biotechnology Holdings's cash flow from others for the
three
months ended in Mar. 2024 was $0.00 Mil.
Lixte Biotechnology Holdings Cash Flow from Operations Related Terms
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIXT has been successfully added to your 